The CRISIS Prevention Study

NCT ID: NCT00395161

Last Updated: 2013-04-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

293 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite strict hand washing, sterile technique, and antibiotic-coated catheters, nosocomial infection and sepsis remain the leading acquired causes of morbidity and mortality in critically ill children. Subsequent use of antibiotics to treat nosocomial infection and sepsis is considered a major attributable factor in the rise of antibiotic-resistant organisms in this population of children. This study will use a double-blind, randomized, controlled trial design to test the hypothesis that daily prophylaxis with metoclopramide, zinc, selenium and glutamine will reduce nosocomial infection and sepsis in critically ill children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite strict hand washing, sterile technique, and antibiotic-coated catheters, nosocomial infection and sepsis remain the leading acquired causes of morbidity and mortality in critically ill children. Subsequent use of antibiotics to treat nosocomial infection and sepsis is considered a major attributable factor in the rise of antibiotic-resistant organisms in this population of children. Presently, "prophylaxis" strategies are used to prevent stress-induced gastrointestinal bleeding; however, no "prophylaxis" strategy is used to prevent stress-induced nosocomial infection and sepsis. When left unopposed, the stress hormone, cortisol, induces lymphocyte apoptosis, lymphopenia, and immune insufficiency. Prolactin is the counter-regulatory stress hormone that prevents cortisol-induced apoptosis and immunosuppression. Zinc, selenium, and glutamine are also important in maintenance of lymphocyte health. Critically ill patients commonly develop hypoprolactinemia secondary to increased central nervous system dopaminergic activity, as well as zinc, selenium, and glutamine deficiency caused by increased utilization and decreased supply. Hypoprolactinemia can be prevented by metoclopramide, a dopamine 2 receptor antagonist commonly used as a prokinetic in children, and zinc, selenium, and glutamine deficiency can be prevented with enteral supplementation. This study will use a double-blind randomized controlled trial design to test the hypothesis that daily prophylaxis with metoclopramide, zinc, selenium and glutamine will reduce nosocomial infection and sepsis in critically ill children.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

zinc selenium glutamine metoclopramide

metoclopramide, zinc, selenium, and glutamine

Group Type EXPERIMENTAL

Metoclopramide

Intervention Type DRUG

0.2 mg/kg/dose IV every 12 hours

Zinc

Intervention Type DRUG

one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)

Glutamine

Intervention Type DIETARY_SUPPLEMENT

one enteral dose daily of glutamine 0.3 gm/kg/day

Selenium

Intervention Type DRUG

one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)

enteral whey protein and IV saline

saline, sterile water, whey protein

Group Type PLACEBO_COMPARATOR

saline

Intervention Type OTHER

equivalent volume of intravenous saline

sterile water

Intervention Type OTHER

equivalent volume of sterile water

selenium

Intervention Type OTHER

equivalent volume of sterile water

whey-protein

Intervention Type DIETARY_SUPPLEMENT

one enteral dose daily of whey-protein

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metoclopramide

0.2 mg/kg/dose IV every 12 hours

Intervention Type DRUG

Zinc

one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)

Intervention Type DRUG

Glutamine

one enteral dose daily of glutamine 0.3 gm/kg/day

Intervention Type DIETARY_SUPPLEMENT

Selenium

one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)

Intervention Type DRUG

saline

equivalent volume of intravenous saline

Intervention Type OTHER

sterile water

equivalent volume of sterile water

Intervention Type OTHER

selenium

equivalent volume of sterile water

Intervention Type OTHER

whey-protein

one enteral dose daily of whey-protein

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Reglan Beneprotein

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

During the initial accrual period for this study, prior to the first interim analysis, patients will be eligible for enrollment if they:

* are between 12 months and less than 18 years; AND
* are within the first 48 hours of the PICU admission; AND
* have an endotracheal tube, central venous catheter (new or old, tunneled or not tunneled), or Foley catheter; AND
* are anticipated to have an indwelling arterial or central venous catheter for blood sampling during the first three days of study enrollment.

After the Data Safety Monitoring Board (DSMB) conducts its first interim evaluation, after enrollment of approximately 200 subjects, a decision will be made by the DSMB concerning enrollment of subjects between 40 weeks gestational age and 12 months. If the DSMB approves enrollment of infants after the first interim analysis, then patients will be eligible for enrollment if they:

* are between 40 weeks gestational age and less than 18 years; AND
* are within the first 48 hours of the PICU admission; AND
* have an endotracheal tube, central venous catheter (new or old, tunneled or not tunneled), or Foley catheter; AND
* are anticipated to have an indwelling arterial or central venous catheter for blood sampling during the first three days of study enrollment.

Exclusion Criteria

During the initial accrual period for this study, prior to the first interim analysis, patients will be ineligible for enrollment if ANY of the following is true or anticipated:

* are less than 1 year age; OR
* are greater than or equal to 18 years of age; OR
* have a known allergy to metoclopramide; OR
* planned removal of endotracheal tube, central venous catheter, AND Foley catheters, within 72 hours of study enrollment, OR
* suspected intestinal obstruction, OR
* intestinal surgery or bowel disruption, OR
* chronic metoclopramide therapy prior to enrollment, OR
* failure to enroll within 48 hours of PICU admission, OR
* readmission to PICU in the previous 28 days, OR
* previously enrolled in this study, OR
* lack of commitment to aggressive intensive care therapies.

After the Data Safety Monitoring Board (DSMB) conducts its first interim evaluation, after enrollment of approximately 200 subjects, a decision will be made by the DSMB concerning enrollment of subjects between 40 weeks gestational age and 12 months. If the DSMB approves enrollment of infants after the first interim analysis, then patients will be ineligible for enrollment if ANY of the following is true or anticipated:

* are less than 40 weeks gestational age; OR
* are greater than or equal to 18 years of age; OR
* have a known allergy to metoclopramide; OR
* planned removal of endotracheal tube, central venous catheter, AND Foley catheters, within 72 hours of study enrollment, OR
* suspected intestinal obstruction
Minimum Eligible Age

12 Months

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

Seattle Children's Hospital

OTHER

Sponsor Role collaborator

Children's Hospital Los Angeles

OTHER

Sponsor Role collaborator

Arkansas Children's Hospital Research Institute

OTHER

Sponsor Role collaborator

Children's Hospital of Michigan

OTHER

Sponsor Role collaborator

University of Pittsburgh

OTHER

Sponsor Role collaborator

Children's National Research Institute

OTHER

Sponsor Role collaborator

University of California, Los Angeles

OTHER

Sponsor Role collaborator

Harborview Injury Prevention and Research Center

OTHER

Sponsor Role collaborator

Michael Dean

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Dean

Data Coordinating Center Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph Carcillo, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Childrens Hospital of Los Angeles

Los Angeles, California, United States

Site Status

University of California Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Children's National Medical Center

Washington D.C., District of Columbia, United States

Site Status

Children's Hospital of Michigan

Detroit, Michigan, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Seattle Children's Hospital

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701. doi: 10.1164/rccm.200207-682OC. Epub 2002 Nov 14.

Reference Type BACKGROUND
PMID: 12433670 (View on PubMed)

Brown RB, Stechenberg B, Sands M, Hosmer D, Ryczak M. Infections in a pediatric intensive care unit. Am J Dis Child. 1987 Mar;141(3):267-70. doi: 10.1001/archpedi.1987.04460030045021.

Reference Type BACKGROUND
PMID: 3812407 (View on PubMed)

Stein F, Trevino R. Nosocomial infections in the pediatric intensive care unit. Pediatr Clin North Am. 1994 Dec;41(6):1245-57. doi: 10.1016/s0031-3955(16)38871-x.

Reference Type BACKGROUND
PMID: 7984384 (View on PubMed)

Ford-Jones EL, Mindorff CM, Pollock E, Milner R, Bohn D, Edmonds J, Barker G, Gold R. Evaluation of a new method of detection of nosocomial infection in the pediatric intensive care unit: the Infection Control Sentinel Sheet System. Infect Control Hosp Epidemiol. 1989 Nov;10(11):515-20. doi: 10.1086/645938.

Reference Type BACKGROUND
PMID: 2685101 (View on PubMed)

Milliken J, Tait GA, Ford-Jones EL, Mindorff CM, Gold R, Mullins G. Nosocomial infections in a pediatric intensive care unit. Crit Care Med. 1988 Mar;16(3):233-7. doi: 10.1097/00003246-198803000-00005.

Reference Type BACKGROUND
PMID: 3277780 (View on PubMed)

Allen U, Ford-Jones EL. Nosocomial infections in the pediatric patient: an update. Am J Infect Control. 1990 Jun;18(3):176-93. doi: 10.1016/0196-6553(90)90183-s.

Reference Type BACKGROUND
PMID: 2194407 (View on PubMed)

Donowitz LG. High risk of nosocomial infection in the pediatric critical care patient. Crit Care Med. 1986 Jan;14(1):26-8. doi: 10.1097/00003246-198601000-00006.

Reference Type BACKGROUND
PMID: 3510104 (View on PubMed)

Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, MacLean LD. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg. 1977 Sep;186(3):241-50. doi: 10.1097/00000658-197709000-00002.

Reference Type BACKGROUND
PMID: 142452 (View on PubMed)

Pellegrini JD, De AK, Kodys K, Puyana JC, Furse RK, Miller-Graziano C. Relationships between T lymphocyte apoptosis and anergy following trauma. J Surg Res. 2000 Feb;88(2):200-6. doi: 10.1006/jsre.1999.5797.

Reference Type BACKGROUND
PMID: 10644489 (View on PubMed)

O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 1995 Oct;222(4):482-90; discussion 490-2. doi: 10.1097/00000658-199522240-00006.

Reference Type BACKGROUND
PMID: 7574928 (View on PubMed)

Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R, Wollbrueck M, Hempelmann G. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med. 1999 Apr;27(4):733-40. doi: 10.1097/00003246-199904000-00026.

Reference Type BACKGROUND
PMID: 10321662 (View on PubMed)

Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000 Jan;181(1):176-80. doi: 10.1086/315214.

Reference Type BACKGROUND
PMID: 10608764 (View on PubMed)

Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell. 2002 Apr;109 Suppl:S97-107. doi: 10.1016/s0092-8674(02)00704-3.

Reference Type BACKGROUND
PMID: 11983156 (View on PubMed)

Fletcher-Chiappini SE, Compton MM, LaVoie HA, Day EB, Witorsch RJ. Glucocorticoid-prolactin interactions in Nb2 lymphoma cells: antiproliferative versus anticytolytic effects. Proc Soc Exp Biol Med. 1993 Mar;202(3):345-52. doi: 10.3181/00379727-202-43545.

Reference Type BACKGROUND
PMID: 8437991 (View on PubMed)

Ayala A, Herdon CD, Lehman DL, DeMaso CM, Ayala CA, Chaudry IH. The induction of accelerated thymic programmed cell death during polymicrobial sepsis: control by corticosteroids but not tumor necrosis factor. Shock. 1995 Apr;3(4):259-67. doi: 10.1097/00024382-199504000-00003.

Reference Type BACKGROUND
PMID: 7600193 (View on PubMed)

Tarcic N, Ovadia H, Weiss DW, Weidenfeld J. Restraint stress-induced thymic involution and cell apoptosis are dependent on endogenous glucocorticoids. J Neuroimmunol. 1998 Feb;82(1):40-46. doi: 10.1016/S0165-5728(97)00186-0.

Reference Type BACKGROUND
PMID: 9526844 (View on PubMed)

Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab. 1972 Dec;35(6):840-51. doi: 10.1210/jcem-35-6-840. No abstract available.

Reference Type BACKGROUND
PMID: 4634485 (View on PubMed)

Yu-Lee LY. Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med. 1997 May;215(1):35-52. doi: 10.3181/00379727-215-44111.

Reference Type BACKGROUND
PMID: 9142136 (View on PubMed)

Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000 Oct;80(4):1523-631. doi: 10.1152/physrev.2000.80.4.1523.

Reference Type BACKGROUND
PMID: 11015620 (View on PubMed)

L Vankrieken. Immulite reproductive hormone assays: multicenter reference range data, 2000.

Reference Type BACKGROUND

HG Friesen. Human prolactin. Ann Rev Coll Phys Surg Can, 11:275- 281, 1978.

Reference Type BACKGROUND

Buckley AR, Buckley DJ. Prolactin regulation of apoptosis-associated gene expression in T cells. Ann N Y Acad Sci. 2000;917:522-33. doi: 10.1111/j.1749-6632.2000.tb05417.x.

Reference Type BACKGROUND
PMID: 11268380 (View on PubMed)

Krishnan N, Thellin O, Buckley DJ, Horseman ND, Buckley AR. Prolactin suppresses glucocorticoid-induced thymocyte apoptosis in vivo. Endocrinology. 2003 May;144(5):2102-10. doi: 10.1210/en.2003-0053.

Reference Type BACKGROUND
PMID: 12697719 (View on PubMed)

Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology. 1996 Dec;137(12):5456-62. doi: 10.1210/endo.137.12.8940371.

Reference Type BACKGROUND
PMID: 8940371 (View on PubMed)

Buckley AR, Buckley DJ, Leff MA, Hoover DS, Magnuson NS. Rapid induction of pim-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells. Endocrinology. 1995 Dec;136(12):5252-9. doi: 10.1210/endo.136.12.7588268.

Reference Type BACKGROUND
PMID: 7588268 (View on PubMed)

Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol. 1999 Apr 1;162(7):4148-56.

Reference Type BACKGROUND
PMID: 10201940 (View on PubMed)

Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. 1996;59(8):599-614. doi: 10.1016/0024-3205(96)00225-1.

Reference Type BACKGROUND
PMID: 8761011 (View on PubMed)

Berczi I. Pituitary hormones and immune function. Acta Paediatr Suppl. 1997 Nov;423:70-5. doi: 10.1111/j.1651-2227.1997.tb18376.x.

Reference Type BACKGROUND
PMID: 9401545 (View on PubMed)

Buckley AR. Prolactin, a lymphocyte growth and survival factor. Lupus. 2001;10(10):684-90. doi: 10.1191/096120301717164912.

Reference Type BACKGROUND
PMID: 11721694 (View on PubMed)

Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci. 1999 Jun 22;876:119-30. doi: 10.1111/j.1749-6632.1999.tb07629.x.

Reference Type BACKGROUND
PMID: 10415600 (View on PubMed)

Fraker PJ, King LE, Laakko T, Vollmer TL. The dynamic link between the integrity of the immune system and zinc status. J Nutr. 2000 May;130(5S Suppl):1399S-406S. doi: 10.1093/jn/130.5.1399S.

Reference Type BACKGROUND
PMID: 10801951 (View on PubMed)

Newsholme P, Curi R, Pithon Curi TC, Murphy CJ, Garcia C, Pires de Melo M. Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease. J Nutr Biochem. 1999 Jun;10(6):316-24. doi: 10.1016/s0955-2863(99)00022-4.

Reference Type BACKGROUND
PMID: 15539305 (View on PubMed)

King LE, Osati-Ashtiani F, Fraker PJ. Apoptosis plays a distinct role in the loss of precursor lymphocytes during zinc deficiency in mice. J Nutr. 2002 May;132(5):974-9. doi: 10.1093/jn/132.5.974.

Reference Type BACKGROUND
PMID: 11983824 (View on PubMed)

Aleksandrowicz J, Starek A, Moszczynski P. [Effect of selenium on peripheral blood in rats chronically exposed to benzene]. Med Pr. 1977;28(6):453-9. Polish.

Reference Type BACKGROUND
PMID: 609322 (View on PubMed)

Szondy Z. The effects of cell number, concentrations of mitogen and glutamine and time of culture on [3H]thymidine incorporation into cervical lymph node lymphocytes stimulated by concanavalin-A. Immunol Lett. 1995 Mar;45(3):167-71. doi: 10.1016/0165-2478(94)00256-q.

Reference Type BACKGROUND
PMID: 7558169 (View on PubMed)

Devins SS, Miller A, Herndon BL, O'Toole L, Reisz G. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med. 1992 Dec;20(12):1644-9. doi: 10.1097/00003246-199212000-00007.

Reference Type BACKGROUND
PMID: 1458939 (View on PubMed)

Van den Berghe G, de Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children. Crit Care Med. 1994 Nov;22(11):1747-53.

Reference Type BACKGROUND
PMID: 7956277 (View on PubMed)

Van den Berghe G, de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med. 1996 Sep;24(9):1580-90. doi: 10.1097/00003246-199609000-00024.

Reference Type BACKGROUND
PMID: 8797634 (View on PubMed)

Le Saux NM, Sekla L, McLeod J, Parker S, Rush D, Jeffery JR, Brunham RC. Epidemic of nosocomial Legionnaires' disease in renal transplant recipients: a case-control and environmental study. CMAJ. 1989 May 1;140(9):1047-53.

Reference Type BACKGROUND
PMID: 2650836 (View on PubMed)

Parra A, Ramirez-Peredo J, Larrea F, Cabrera V, Coutino B, Torres I, Angeles A, Perez-Romano B, Ruiz-Arguelles G, Ruiz-Arguelles A. Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin Endocrinol (Oxf). 2001 Jun;54(6):731-8. doi: 10.1046/j.1365-2265.2001.01262.x.

Reference Type BACKGROUND
PMID: 11422107 (View on PubMed)

Parra A, Ramirez-Peredo J. The uncoupled couple? Prolactin and CD4 lymphocytes in HIV infection. Med Hypotheses. 1999 Nov;53(5):425-8. doi: 10.1054/mehy.1999.0930.

Reference Type BACKGROUND
PMID: 10616045 (View on PubMed)

Ijaiya K, Roth B, Schwenk A. The effects of arginine, insulin and metoclopramide on growth hormone, prolactin and cortisol release in children. Clin Endocrinol (Oxf). 1980 Jun;12(6):589-94. doi: 10.1111/j.1365-2265.1980.tb01380.x.

Reference Type BACKGROUND
PMID: 6994940 (View on PubMed)

LL Brunton. Agents affecting gastrointestinal water flux and motility. In Limbird LE Hardman JG, editor, Goodman and Gilman's The Pharmacological Basis of Therapeutics, pages 931-933. McGraw-Hill, New York, 9th edition, 1996.

Reference Type BACKGROUND

F Shann, editor. Drug Doses. Collective Pty Ltd., Melbourne, 12th edition, 2003.

Reference Type BACKGROUND

PR Dallman. White blood cells: developmental changes in numbers. In Ruolph CD Rudolph AM, Hoffman JIE, editor, Pediatrics, page 1061. Appleton and Lange, Norwalk CT, 19th edition, 1987.

Reference Type BACKGROUND

Anonymous. Immunization in special clinical circumstances. In LK Pickering, editor, 2000 Redbook: Report of the Committee of Infectious Diseases, page 59. Academy of Pediatrics, Elk Grove Village, IL, 25th edition, 2000.

Reference Type BACKGROUND

E.R. Stiehm. Immunologic disorders in infants and children. W.B. Saunders, Philadelphia, PA, 1989.

Reference Type BACKGROUND

Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001 Jun 1;166(11):6952-63. doi: 10.4049/jimmunol.166.11.6952.

Reference Type BACKGROUND
PMID: 11359857 (View on PubMed)

Gurevich P, Ben-Hur H, Czernobilsky B, Nyska A, Zuckerman A, Zusman I. Pathology of lymphoid organs in low birth weight infants subjected to antigen-related diseases: a morphological and morphometric study. Pathology. 1995 Apr;27(2):121-6. doi: 10.1080/00313029500169702.

Reference Type BACKGROUND
PMID: 7567136 (View on PubMed)

Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol. 2000 Dec;1(6):496-501. doi: 10.1038/82741.

Reference Type BACKGROUND
PMID: 11101871 (View on PubMed)

Zellweger R, Wichmann MW, Ayala A, Chaudry IH. Metoclopramide: a novel and safe immunomodulating agent for restoring the depressed macrophage immune function after hemorrhage. J Trauma. 1998 Jan;44(1):70-7. doi: 10.1097/00005373-199801000-00006.

Reference Type BACKGROUND
PMID: 9464751 (View on PubMed)

Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol. 1996 Dec 15;157(12):5748-54.

Reference Type BACKGROUND
PMID: 8955229 (View on PubMed)

Knoferl MW, Angele MK, Ayala A, Cioffi WG, Bland KI, Chaudry IH. Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage. Am J Physiol Cell Physiol. 2000 Jul;279(1):C72-80. doi: 10.1152/ajpcell.2000.279.1.C72.

Reference Type BACKGROUND
PMID: 10898718 (View on PubMed)

Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol. 2005 Mar 15;174(6):3765-72. doi: 10.4049/jimmunol.174.6.3765.

Reference Type BACKGROUND
PMID: 15749917 (View on PubMed)

Yavagal DR, Karnad DR, Oak JL. Metoclopramide for preventing pneumonia in critically ill patients receiving enteral tube feeding: a randomized controlled trial. Crit Care Med. 2000 May;28(5):1408-11. doi: 10.1097/00003246-200005000-00025.

Reference Type BACKGROUND
PMID: 10834687 (View on PubMed)

Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. Lancet. 2004 May 22;363(9422):1683-8. doi: 10.1016/S0140-6736(04)16252-1.

Reference Type BACKGROUND
PMID: 15158629 (View on PubMed)

Fischer Walker C, Black RE. Zinc and the risk for infectious disease. Annu Rev Nutr. 2004;24:255-75. doi: 10.1146/annurev.nutr.23.011702.073054.

Reference Type BACKGROUND
PMID: 15189121 (View on PubMed)

Baqui AH, Black RE, El Arifeen S, Yunus M, Zaman K, Begum N, Roess AA, Santosham M. Zinc therapy for diarrhoea increased the use of oral rehydration therapy and reduced the use of antibiotics in Bangladeshi children. J Health Popul Nutr. 2004 Dec;22(4):440-2.

Reference Type BACKGROUND
PMID: 15663177 (View on PubMed)

Raqib R, Roy SK, Rahman MJ, Azim T, Ameer SS, Chisti J, Andersson J. Effect of zinc supplementation on immune and inflammatory responses in pediatric patients with shigellosis. Am J Clin Nutr. 2004 Mar;79(3):444-50. doi: 10.1093/ajcn/79.3.444.

Reference Type BACKGROUND
PMID: 14985220 (View on PubMed)

Bhatnagar S, Bahl R, Sharma PK, Kumar GT, Saxena SK, Bhan MK. Zinc with oral rehydration therapy reduces stool output and duration of diarrhea in hospitalized children: a randomized controlled trial. J Pediatr Gastroenterol Nutr. 2004 Jan;38(1):34-40. doi: 10.1097/00005176-200401000-00010.

Reference Type BACKGROUND
PMID: 14676592 (View on PubMed)

Sazawal S, Black RE, Menon VP, Dinghra P, Caulfield LE, Dhingra U, Bagati A. Zinc supplementation in infants born small for gestational age reduces mortality: a prospective, randomized, controlled trial. Pediatrics. 2001 Dec;108(6):1280-6. doi: 10.1542/peds.108.6.1280.

Reference Type BACKGROUND
PMID: 11731649 (View on PubMed)

Darlow BA, Austin NC. Selenium supplementation to prevent short-term morbidity in preterm neonates. Cochrane Database Syst Rev. 2003;2003(4):CD003312. doi: 10.1002/14651858.CD003312.

Reference Type BACKGROUND
PMID: 14583967 (View on PubMed)

van den Berg A, van Elburg RM, Westerbeek EA, Twisk JW, Fetter WP. Glutamine-enriched enteral nutrition in very-low-birth-weight infants and effects on feeding tolerance and infectious morbidity: a randomized controlled trial. Am J Clin Nutr. 2005 Jun;81(6):1397-404. doi: 10.1093/ajcn/81.6.1397.

Reference Type BACKGROUND
PMID: 15941893 (View on PubMed)

Boelens PG, Houdijk AP, Fonk JC, Puyana JC, Haarman HJ, von Blomberg-van der Flier ME, van Leeuwen PA. Glutamine-enriched enteral nutrition increases in vitro interferon-gamma production but does not influence the in vivo specific antibody response to KLH after severe trauma. A prospective, double blind, randomized clinical study. Clin Nutr. 2004 Jun;23(3):391-400. doi: 10.1016/j.clnu.2003.09.002.

Reference Type BACKGROUND
PMID: 15158303 (View on PubMed)

Yalcin SS, Yurdakok K, Tezcan I, Oner L. Effect of glutamine supplementation on diarrhea, interleukin-8 and secretory immunoglobulin A in children with acute diarrhea. J Pediatr Gastroenterol Nutr. 2004 May;38(5):494-501. doi: 10.1097/00005176-200405000-00007.

Reference Type BACKGROUND
PMID: 15097437 (View on PubMed)

Leteurtre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F, Lacroix J, Leclerc F. Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making. 1999 Oct-Dec;19(4):399-410. doi: 10.1177/0272989X9901900408.

Reference Type BACKGROUND
PMID: 10520678 (View on PubMed)

Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, Gottesman R, Joffe A, Pfenninger J, Hubert P, Lacroix J, Leclerc F. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 2003 Jul 19;362(9379):192-7. doi: 10.1016/S0140-6736(03)13908-6.

Reference Type BACKGROUND
PMID: 12885479 (View on PubMed)

Doughty LA, Kaplan SS, Carcillo JA. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med. 1996 Jul;24(7):1137-43. doi: 10.1097/00003246-199607000-00012.

Reference Type BACKGROUND
PMID: 8674325 (View on PubMed)

Pollack MM, Patel KM, Ruttimann UE. The Pediatric Risk of Mortality III--Acute Physiology Score (PRISM III-APS): a method of assessing physiologic instability for pediatric intensive care unit patients. J Pediatr. 1997 Oct;131(4):575-81. doi: 10.1016/s0022-3476(97)70065-9.

Reference Type BACKGROUND
PMID: 9386662 (View on PubMed)

Slota M, Green M, Farley A, Janosky J, Carcillo J. The role of gown and glove isolation and strict handwashing in the reduction of nosocomial infection in children with solid organ transplantation. Crit Care Med. 2001 Feb;29(2):405-12. doi: 10.1097/00003246-200102000-00034.

Reference Type BACKGROUND
PMID: 11246324 (View on PubMed)

Leclerc F, Leteurtre S, Duhamel A, Grandbastien B, Proulx F, Martinot A, Gauvin F, Hubert P, Lacroix J. Cumulative influence of organ dysfunctions and septic state on mortality of critically ill children. Am J Respir Crit Care Med. 2005 Feb 15;171(4):348-53. doi: 10.1164/rccm.200405-630OC. Epub 2004 Oct 29.

Reference Type BACKGROUND
PMID: 15516535 (View on PubMed)

Klein BS, Perloff WH, Maki DG. Reduction of nosocomial infection during pediatric intensive care by protective isolation. N Engl J Med. 1989 Jun 29;320(26):1714-21. doi: 10.1056/NEJM198906293202603.

Reference Type BACKGROUND
PMID: 2733733 (View on PubMed)

Carcillo J, Holubkov R, Dean JM, Berger J, Meert KL, Anand KJ, Zimmerman J, Newth CJ, Harrison R, Willson DF, Nicholson C; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Rationale and design of the pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. JPEN J Parenter Enteral Nutr. 2009 Jul-Aug;33(4):368-74. doi: 10.1177/0148607108327392. Epub 2009 Apr 14.

Reference Type BACKGROUND
PMID: 19380753 (View on PubMed)

Carcillo JA, Dean JM, Holubkov R, Berger J, Meert KL, Anand KJ, Zimmerman J, Newth CJ, Harrison R, Burr J, Willson DF, Nicholson C; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Collaborative Pediatric Critical Care Research Network (CPCCRN). The randomized comparative pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. Pediatr Crit Care Med. 2012 Mar;13(2):165-73. doi: 10.1097/PCC.0b013e31823896ae.

Reference Type RESULT
PMID: 22079954 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U01HD049934

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Statins for the Early Treatment of Sepsis
NCT00528580 TERMINATED PHASE2
Zinc Supplementation in Pediatric Sepsis
NCT05366595 COMPLETED PHASE2
Early Vasopressors in Sepsis
NCT05179499 RECRUITING PHASE3
Citrulline in Severe Sepsis
NCT01474863 COMPLETED PHASE2